All In Biotech

Drug Trial Radar · NCT04241549

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

A Phase 1 Study of Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Mar 25, 2020

Primary completion

Jul 19, 2021

Study completion Jul 19, 2021

Sponsor

Lead sponsor
OncoVerity, Inc.Industry
Sponsor type
Industry
Collaborators
argenx; Janssen Pharmaceutical K.K.
First posted
Jan 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are not candidates for intensive treatment.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

  • CusatuzumabDrug

    Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.

  • AzacitidineDrug

    Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 and Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 3 years
  2. Part 1 and Part 2: Number of Participants with Dose-Limiting Toxicity (DLTs)Time frame: Up to 42 days
  3. Part 1 and Part 2: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)Time frame: Up to 42 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Fukushima Medical University Hospital

    Fukushima, Japan

  • Gunmaken Saiseikai Maebashi Hospital

    Maebashi, Japan

  • Osaka City General Hospital

    Osaka, Japan

  • NTT Medical Center Tokyo

    Tokyo, Japan

  • University of Fukui Hospital

    Yoshida, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.